Tezspire™ (tezepelumab injection) now available in Canada for severe asthma
/CNW/ - Today, AstraZeneca and Amgen announced the Canadian availability of Tezspire™ (tezepelumab injection), indicated for the add-on maintenance treatment...
Stay updated with breaking news from Inflammatory Disorders. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/CNW/ - Today, AstraZeneca and Amgen announced the Canadian availability of Tezspire™ (tezepelumab injection), indicated for the add-on maintenance treatment...
A recent study published in Diagnostics identifies multimodal imaging traits to distinguish primary inflammatory choriocapillaropathies, such as multiple evanescent white dot syndrome and idiopathic multifocal choroiditis, from primary photoreceptoritis.
AstraZeneca’s Tezspire (tezepelumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. The ...
First and only biologic recommended for EU approval in patients with severe asthma with no phenotype or biomarker limitations. AstraZeneca's Tezspire has been recommended for marketing authorisation... | July 25, 2022
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase 3 and PATHWAY Phase 2b trials showed...